Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Radboud University Medical Center
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up.
Note: informed consent may be obtained prior to start of the specified screening window.
Note: procedures conducted as part of the subject's routine clinical management (e.g. blood count) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.
≥ 18 year old men who use or will start with abiraterone.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Feasible to collect blood samples from.
You may not be if
Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:
Malabsorption syndrome.
Major resection of the stomach or small bowel.
Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
Unable or unwilling to discontinue use of prohibited medications listed in APPENDIX 3 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of day 1 and for the duration of the study.
Concurrent use of other substances known or likely to interfere with the pharmacokinetics of abiraterone.
Clareo Health | Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake
